HARBIN, China, April 7, 2011 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (NASDAQ: CSKI), a leading fully integrated pharmaceutical company in the People's Republic of China ("PRC"), today announced that the Company, jointly with Heilongjiang Traditional Chinese Medical University ("HTCMU"), has obtained production licenses for thirteen new medical products from the Heilongjiang Food and Drug Administration ("Heilongjiang FDA") in China. These thirteen products include:No.
Kang Xi Eye Patch2
KangXi Dental Ulcer Membrane3
KangXi Anti-virus Mouthwash4
KangXi Dental Ulcer Mouthwash5
KangXi Snore Stopper6
Kang Xi Periarthritis Shoulder Patch7
KangXi Cervical Vertebrae Patch8
KangXi Lumbar Patch9
KangXi Rheumatoid Patch10
KangXi Hyperostosis Patch11
BiChang Nose Patch12
YuFu Scar Patch13
YuFu Wound Healing PatchChina Sky One is preparing for trial production and searching for the best production process for these thirteen products, which the Company expects to introduce to the market as soon as the fourth quarter of 2011.
"We are pleased to obtain production licenses for these exciting new products, which as a group we believe will contribute materially to China Sky One's revenue and net income in 2012," commented Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical. "As these mostly external-use medical products dovetail well with our existing production facilities and sales network, we expect to manufacture and sell them efficiently without much extra effort. Going forward, we plan to strengthen our partnership with research institutions such as HTCMU, leveraging their R&D capabilities to enrich our product portfolio and improve the Company's profitability."
About China Sky One Medical, Inc. China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company, Harbin First Bio-Engineering Company Limited, Heilongjiang Tianlong Pharmaceutical, Inc. and Peng Lai Jin Chuang Pharmaceutical Company, the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.cski.com.cn .
Safe Harbor Statement
Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the Company's brand recognition and product quality. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, the potential of introduced or undetected flaws and defects in products, consumer acceptance of new products to be launched, including the thirteen new medical products for which the Company received production license approval from Heilongjiang FDA, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.
Investor Relations Contact:China Sky One Medical
CCG Investor RelationsHongyu Pan, CFO
Crocker Coulson, PresidentEmail: email@example.com
|SOURCE China Sky One Medical, Inc.|
Copyright©2010 PR Newswire.
All rights reserved